Foley & Larder LLP represented TCG Crossover, lead investor. Adverum Biotechnologies has agreed to sell approximately 106.25 million shares of its common stock at a price per share...
Adverum Biotechnologies’ $127.5 Million Private Placement
Silence Therapeutics’ $120 Million Private Placement
Foley & Larder LLP represented investor TCG Crossover. Silence Therapeutics plc (Nasdaq: SLN), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing...
Mineralys Therapeutics’ $120 Million Private Financing
Foley & Larder LLP represented TCG Crossover, as lead investor. Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension,...
COMPASS Pathways’ $285 Million Financing
Foley & Lardner LLP represented TCGX as a lead investor in the financing of COMPASS Pathways. COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to...
KalVista Pharmaceuticals’ $58 Million Direct Offering
Foley & Lardner LLP represented TCG Crossover on the deal. TCG Crossover acted as the lead investor in KalVista Pharmaceuticals’ $58 million registered direct offering. KalVista...
LoftyInc Capital’s $10 Million Fund Formation
Foley & Lardner advised LoftyInc Capital on the deal. LoftyInc Capital, a pan-African VC firm, announced the launch of its third fund – LoftyInc Afropreneurs Fund 3...